Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 305 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... February 21, 2023 Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... April 23, 2024 Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 Load more HOT NEWS Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz EMA Recommends Extension of Indications for Tegafur ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC...
